18 JUNE – 18h20
|
SYMPOSIUM – Room MIZAR
A GLOBAL COMMITMENT TO BREAST CANCER RESEARCH AND TREATMENT
Chair A. Goldhirsch
Aromatase Inhibitors – from research to care: the story of BIG 1-98
C. Tondini
Biological heterogeneity of Breast Cancer: lessons from Aromatase Inhibitor trials
G. Viale
Looking into the future: innovation in Breast Cancer care
P. Pronzato
Supported by Novartis |
| 19 JUNE – 07h30 |
BREAKFAST WITH THE EXPERT – Room VESTA
CIRCULATING TUMOR CELLS: A NEW TOOL IN MANAGEMENT OF BREAST CANCER PATIENTS
Chair: M.T. Sandri
Cell search four years later
R. Mc Cormack
Circulating tumor cells in peripheral blood of early breast cancer patients – results from the German SUCCESS trial
B. Rack
Circulating tumor cells in early and advanced breast cancer: the EIO experience
F. Nolé
Supported by Veridex |
| 19 JUNE – 10h20 |
COFFEE WITH THE EXPERT – Room ANDROMEDA
ORAL CYTOTOXIC: CHALLENGING COMPLIANCE OR IMPROVING TOLLERANCE
Chair: F. Nolé
Speaker: G. Mustacchi
Supported by Pierre Fabre Pharma
|
| 19 JUNE - 12h30 |
SYMPOSIUM – Room QUASAR
REFINING KNOWLEDGE IN ONCOLOGY: TREATMENT OF HER2-POSITIVE DISEASE
Chair: G. Curigliano
Targeted Therapy, efficacy & safety: focus on resistance and toxicity
A. Di Leo
Novel options for women with HER2-positive disease
E. Winer
Supported by GlaxoSmithKline |
| 19 JUNE – 16h00 |
COFFEE WITH THE EXPERT – Room ANDROMEDA
TIMING, DURATION AND EFFICACY OF OVARIAN FUNCTION SUPPRESSION WITH LHRH ANALOGS AS ADJUVANT ENDOCRINE THERAPY FOR PREMENOPAUSAL WOMEN WITH BREAST CANCER
Relatore: R. Torrisi
Chairman: M. De Laurentiis
Supported by Ipsen
|
| 19 JUNE - 18h00 |
SYMPOSIUM - ROOM MIZAR
Anti angiogenesis and breast cancer treatment
Chair: S. Cinieri - M. Colleoni
Bevacizumab for women with advanced breast cancer
G. Mustacchi
Using anti angiogenesis and other targeted therapy
L. Orlando
The anti angiogenesis a challenge for the adjuvant setting
V. Lorusso
Supported by Roche |
| 20 JUNE – 07h30 |
BREAKFAST WITH THE EXPERT – Room VESTA
GENE PROFILING IN THE CLINICAL PRACTICE, THE LATEST NEWS ON MAMMAPRINT
Chair: G. Mustacchi
Speaker: F. De Snoo
Supported by Agendia |
| 20 JUNE – 10h30 |
COFFEE WITH THE EXPERT – Room ANDROMEDA
METHODOLOGICAL INTERPRETATION OF CLINICAL STUDIES: A COMPARISON AMONG AROMATASE INHIBITORS
Chair: S. Cinieri
Speaker: G. Curigliano
Supported by Pfizer |
| 20 JUNE – 12h50 |
SYMPOSIUM – Room QUASAR
ANTI HER2 TREATMENTS TODAY
Chair: A. Goldhirsch
Using anti HER2 drugs in adjuvant treatment
M. De Laurentiis
Combining targeted treatments: is the combination of targeted treatments essential for improving efficacy of therapy?
L. Biganzoli
Supported by Roche |
| 20 JUNE – 15h45 |
COFFEE WITH THE EXPERT - Room ANDROMEDA
LONG TERM RESULTS OF ADJUVANT AROMATASE INHIBITORS: ATAC
Chair: S. Cinieri
Speaker: A. Howell
Supported by Astrazeneca |
HOME PAGE
Wed, 18 june 2008